Remdesivir- Ivermectin Combination Therapy in Severe Covid-19

Remdesivir Versus Remdesivir- Ivermectin Combination Therapy in Severe and Critically Ill Covid-19

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04944082

Enrollment

Registered

2021-06-29

Start date

2021-07-01

Completion date

2021-12-31

Last updated

2021-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

Recent study reported in vitro synergistic interaction between two FDA approved drugs, remdesivir (RDV) and ivermectin (IVM) resulting in enhanced antiviral activity against SARS-CoV-2, the causative pathogen of COVID-19. The aim of the current study is comparing the efficacy and safety of combining remdesivir and ivermectin versus using remdesivir alone in patients with severe COVID-19.

Interventions

DRUGIvermectin

(The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult, hospitalized severe COVID-19 patients; both genders; given informed consent (COVID-19 infection confirmed by PCR, severe illness is defined as patients with SpO2 ≤94% on room air, including patients on supplemental oxygen).

Exclusion criteria

* patients under 18 years old, pregnant ladies, advanced renal diseases (cr. Clearance \< 30 ml/hr), raised liver enzymes\> 3 folds of normal, arrhythmia.

Design outcomes

Primary

Measure	Time frame	Description
1- Improvement in level of oxygenation	By arterial blood gas and non-invasive pulse oximeter at date of randomisation, after 1 hour then on daily bases in stable cases till time of patient discharge or death	Change in partial pressure of Oxygen and oxygen saturation
2- Need for ventilator support	From date of randomisation to patient discharge from hospital or death.	either noninvasive or invasive mechanical ventilation.
3- Length of hospital stay	From date of randomisation to date of patient discharge from hospital or death.	duration of admission in days
4- Development of complication	From starting to the end of ivermectin therapy (0 to the end of 4th day)	allergic reactions, arrhythmia, hepatic toxicity.....
5- Mortality	Through study completion, an average of 3 months	mortality rates in both groups

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026